AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid feed placement at the front of the pen adjacent to the milk feeder (ADJ)
Number of subjects: 60
Study 32389476 — intervention group
Group type: COMPARATOR
Intervention: Solid feed placement at the back of the pen on the opposite side from the milk feeder (OPP)
Number of subjects: 60
Study 32389476 — intervention group
Group type: EXPERIMENTAL
Intervention: ADJ treatment
Number of subjects: 60
Study 36040766 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive e-visits
Number of subjects: 125
Study 36040766 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 125
Study 33485703 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical zinc sulphate (n = 20)
Number of subjects: 30
Study 33485703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 30
Study 33485703 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 30
Study 35341328 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 20
Study 35341328 — intervention group
Group type: COMPARATOR
Intervention: Control (nonomeprazole)
Number of subjects: 20
Study 34759002 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a physiotherapy led exercise programme
Number of subjects: 392
Study 34759002 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study 32652963 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BMI and BF% cut-offs
Number of subjects: 483
Study 32652963 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI cut-offs for predicting high BF%
Number of subjects: 483
Study 32652963 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender control in regression analyses
Number of subjects: 483
Study 34955298 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology Massage
Number of subjects: 36
Study 34955298 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology Massage with Passive Music Therapy
Number of subjects: 36
Study 34955298 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 34805398 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate combined with iguratimod
Number of subjects: 268
Study 34805398 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 268
Study 34805398 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (HCG)
Number of subjects: 268
Study 36067687 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation Group (SRG)
Number of subjects: 50
Study 36067687 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Exercise Group (DEG)
Number of subjects: 50
Study 33441686 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction with manikin feedback
Number of subjects: 64
Study 33441686 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led method
Number of subjects: 64
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole (0.2 mg/kg)
Number of subjects: 48
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1 mg/kg)
Number of subjects: 48
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Aminopyridine (0.5 mg/kg)
Number of subjects: 48
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil + 4-Aminopyridine
Number of subjects: 48
Study 34704354 — intervention group
Group type: COMPARATOR
Intervention: Control (physiological saline solution at 0.1 mL/kg)
Number of subjects: 48
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole + Flumazenil
Number of subjects: 48
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole + 4-Aminopyridine
Number of subjects: 48
Study 34704354 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole + Flumazenil + 4-Aminopyridine
Number of subjects: 48
Study 34772301 — intervention group
Group type: EXPERIMENTAL
Intervention: Coolsense
Number of subjects: 64
Study 34772301 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 64
Study 34840701 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Number of subjects: 68
Study 34840701 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 68
Study 32003833 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 30000
Study 32003833 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (class effect)
Number of subjects: 30000
Study 32003833 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 30000
Study 33605543 — intervention group
Group type: EXPERIMENTAL
Intervention: dHAM (dried human amnion derived membrane)
Number of subjects: 31
Study 33605543 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study 33605543 — intervention group
Group type: EXPERIMENTAL
Intervention: dHAM
Number of subjects: 31
Study 33833219 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to BIP-SCZ (bipolar disorder and schizophrenia combined)
Number of subjects: 0
Study 33833219 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic instruments of BMI
Number of subjects: 0
Study 33833219 — intervention group
Group type: COMPARATOR
Intervention: Genetic liabilities to COVID-19 phenotypes
Number of subjects: 0
Study 33032804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine (100 μg)
Number of subjects: 83
Study 33032804 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block (BNF) with 25 mL of 0.375% ropivacaine
Number of subjects: 83
Study 33032804 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 83
Study 33032804 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block (BNF) with 25 mL of 0.25% ropivacaine
Number of subjects: 83
Study 36202690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W
Number of subjects: 969
Study 36202690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 969
Study 33546942 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose anthocyanins (201 mg)
Number of subjects: 31
Study 33546942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose anthocyanins (47 mg)
Number of subjects: 31
Study 33546942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 33198608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Number of subjects: 11016
Study 33198608 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Number of subjects: 11016
Study 33198608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor added to aspirin
Number of subjects: 11016
Study 33198608 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to aspirin
Number of subjects: 11016
Study 33198608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11016
Study 33198608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11016
Study 35061867 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5674
Study 35061867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5674
Study 33115598 — intervention group
Group type: EXPERIMENTAL
Intervention: CBJ with 1000 mg of vitamin C (NC)
Number of subjects: 18
Study 33115598 — intervention group
Group type: COMPARATOR
Intervention: CBJ with matched placebo (N)
Number of subjects: 18
Study 32524145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound‐mediated transdermal drug delivery (group U)
Number of subjects: 58
Study 32524145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine intradermal injection (group I)
Number of subjects: 58
Study 32524145 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 58
Study 32698620 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about a negative health outcome in the future
Number of subjects: 0
Study 32698620 — intervention group
Group type: EXPERIMENTAL
Intervention: Facing an actual health outcome (consuming an unhealthy food)
Number of subjects: 0
Study 32698620 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact biases associated with behavioral motivation
Number of subjects: 0
Study 34478693 — intervention group
Group type: EXPERIMENTAL
Intervention: HF disease management program (HF-DMP)
Number of subjects: 125
Study 34478693 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study 32566244 — intervention group
Group type: EXPERIMENTAL
Intervention: PSPAF intervention
Number of subjects: 20
Study 32566244 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 34498896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovering Together (RT) intervention
Number of subjects: 58
Study 34498896 — intervention group
Group type: COMPARATOR
Intervention: Health education attention placebo control
Number of subjects: 58
Study 33267853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to stop khat chewing
Number of subjects: 605
Study 33267853 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reevaluation
Number of subjects: 605
Study 33267853 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental reevaluation
Number of subjects: 605
Study 33267853 — intervention group
Group type: EXPERIMENTAL
Intervention: Social liberation
Number of subjects: 605
Study 33267853 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional substances daily, khat dependency, early age initiation of khat chewing
Number of subjects: 605
Study 33748282 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg orally 30 min before surgery
Number of subjects: 60
Study 33748282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33990064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity in adolescence
Number of subjects: 843
Study 33990064 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous physical activity from youth to adulthood
Number of subjects: 843
Study 34175714 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped‐care (SC)
Number of subjects: 53
Study 34175714 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 53
Study 35946240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% minocycline mouth rinse prescribed along with vitamin supplement and topical anesthetic gel
Number of subjects: 60
Study 35946240 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic gel and vitamin supplement alone
Number of subjects: 60
Study 33704389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear masks
Number of subjects: 200
Study 33704389 — intervention group
Group type: COMPARATOR
Intervention: Covered masks
Number of subjects: 200
Study 32711948 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction (rotatable wooden toy)
Number of subjects: 216
Study 32711948 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distraction (toy wristband)
Number of subjects: 216
Study 32711948 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study 35568376 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention (6 telephone-delivered individual coaching sessions over 12 weeks)
Number of subjects: 250
Study 35568376 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention
Number of subjects: 250
Study 35568376 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm
Number of subjects: 250
Study 33404150 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 234
Study 33404150 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent buprenorphine-naloxone (ACB)
Number of subjects: 234
Study 33404150 — intervention group
Group type: COMPARATOR
Intervention: No behavioral counseling
Number of subjects: 234
Study 33404150 — intervention group
Group type: COMPARATOR
Intervention: No ACB
Number of subjects: 234
Study 33404150 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 234
Study 33115831 — intervention group
Group type: EXPERIMENTAL
Intervention: CSNAT-I (Carer Support Needs Assessment Tool intervention)
Number of subjects: 437
Study 33115831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 437
Study 35381095 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (IMEG) at 1000- and 1500-mg doses twice daily
Number of subjects: 0
Study 35381095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33801189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 39
Study 33801189 — intervention group
Group type: COMPARATOR
Intervention: General gymnastics (CG)
Number of subjects: 39
Study 33827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible treatment for children with profound autism
Number of subjects: 0
Study 33827289 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for research
Number of subjects: 0
Study 32721580 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 237
Study 32721580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 33713618 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 200
Study 32244628 — intervention group
Group type: EXPERIMENTAL
Intervention: Five sets of five bench press repetitions at 90% 1 repetition maximum (1RM)
Number of subjects: 10
Study 32244628 — intervention group
Group type: EXPERIMENTAL
Intervention: Five sets of three bench press repetitions at 95% 1 repetition maximum (1RM)
Number of subjects: 10
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg twice daily (BID)
Number of subjects: 106
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg at bedtime (HS)
Number of subjects: 106
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: APT‐1011 1.5 mg BID
Number of subjects: 106
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: APT‐1011 1.5 mg HS
Number of subjects: 106
Study 35181572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg BID
Number of subjects: 106
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: APT‐1011 3 mg HS
Number of subjects: 106
Study 35181572 — intervention group
Group type: EXPERIMENTAL
Intervention: All active groups
Number of subjects: 106
Study 33966331 — intervention group
Group type: EXPERIMENTAL
Intervention: HBAI20 vaccine
Number of subjects: 133
Study 33966331 — intervention group
Group type: COMPARATOR
Intervention: HBVaxPro®-10 µg
Number of subjects: 133
Study 35271409 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise with biceps vibration
Number of subjects: 0
Study 35271409 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise without biceps vibration
Number of subjects: 0
Study 35271409 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movement with biceps vibration
Number of subjects: 0
Study 35271409 — intervention group
Group type: COMPARATOR
Intervention: Passive movement without biceps vibration
Number of subjects: 0
Study 33183032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ningxin Anshen Decoction (NXAS)
Number of subjects: 61
Study 33183032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32368860 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 17
Study 35526235 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual potency of factor VIII concentrate
Number of subjects: 50
Study 35526235 — intervention group
Group type: COMPARATOR
Intervention: Label potency of factor VIII concentrate
Number of subjects: 50
Study 34881912 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychotherapy
Number of subjects: 113
Study 35604581 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intradialytic moderate-intensity aerobic exercise training program (3 times a week for 60 min)
Number of subjects: 24
Study 35604581 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 24
Study 35604581 — intervention group
Group type: EXPERIMENTAL
Intervention: EX group
Number of subjects: 24
Study 34864978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25h)
Number of subjects: 120
Study 34864978 — intervention group
Group type: COMPARATOR
Intervention: Fast thrombolytic regimen (50 mg of rtPA infused in 6h)
Number of subjects: 120
Study 36409949 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic health assessment with individualized feedback
Number of subjects: 296
Study 36409949 — intervention group
Group type: COMPARATOR
Intervention: Screening program without feedback (Control)
Number of subjects: 296
Study 36409949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 296
Study 33107745 — intervention group
Group type: EXPERIMENTAL
Intervention: IV administration of cefquinome sulfate (2 mg/kg)
Number of subjects: 432
Study 33107745 — intervention group
Group type: EXPERIMENTAL
Intervention: IM administration of injectable cefquinome sulfate (2 mg/kg)
Number of subjects: 432
Study 33107745 — intervention group
Group type: EXPERIMENTAL
Intervention: IM administration of injectable cefquinome sulfate suspension (2 mg/kg)
Number of subjects: 432
Study 34621044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg orally every day
Number of subjects: 0
Study 34621044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33440015 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 20
Study 33440015 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 20
Study 33440015 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel® supraglottic airway device
Number of subjects: 20
Study 33440015 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube intubation by direct laryngoscopy
Number of subjects: 20
Study 33440015 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask (LM)
Number of subjects: 20
Study 33440015 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal tube (LT)
Number of subjects: 20
Study 33440015 — intervention group
Group type: COMPARATOR
Intervention: I-gel
Number of subjects: 20
Study 33440015 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 20
Study 32266599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 15 mg/kg every 12 h
Number of subjects: 19
Study 32266599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 12 mg/kg every 8 h
Number of subjects: 19
Study 32594832 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based occupational therapy telerehabilitation via smartphone (Caspar Health e-system and mobile app)
Number of subjects: 31
Study 32594832 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil instructions for the home programme
Number of subjects: 31
Study 33595142 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) 100 IU/2 mL in each adductor magnus and each triceps surae
Number of subjects: 55
Study 33595142 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (2 mL)
Number of subjects: 55
Study 33595142 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 55
Study 32790724 — intervention group
Group type: EXPERIMENTAL
Intervention: CPEC projects with land acquisition by force or inadequate compensation
Number of subjects: 250
Study 32790724 — intervention group
Group type: EXPERIMENTAL
Intervention: Regions with economic zones
Number of subjects: 250
Study 32790724 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities with development projects
Number of subjects: 250
Study 32790724 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of financial outcomes for CPEC projects
Number of subjects: 250
Study 35470143 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly malignant EEG patterns
Number of subjects: 262
Study 35470143 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant EEG patterns
Number of subjects: 262
Study 35470143 — intervention group
Group type: COMPARATOR
Intervention: Benign EEG patterns
Number of subjects: 262
Study 35470143 — intervention group
Group type: COMPARATOR
Intervention: Continuous EEG background
Number of subjects: 262
Study 35470143 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG background and amount of discharges
Number of subjects: 262
Study 33471640 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors alone
Number of subjects: 585
Study 33471640 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors plus basal insulin
Number of subjects: 585
Study 33471640 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin regimen
Number of subjects: 585
Study 34081111 — intervention group
Group type: EXPERIMENTAL
Intervention: BHB + BLG
Number of subjects: 8
Study 34081111 — intervention group
Group type: EXPERIMENTAL
Intervention: BLG
Number of subjects: 8
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2FPO3/CaCO3 toothpaste with 1,378 microg F/g of total soluble fluoride (TSF)
Number of subjects: 10
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged toothpaste with 1,160 microg F/g TSF
Number of subjects: 10
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged toothpaste with 900 microg F/g TSF
Number of subjects: 10
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged toothpaste with 597 microg F/g TSF
Number of subjects: 10
Study 35789454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth tissue‐borne expander
Number of subjects: 46
Study 35789454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne expander
Number of subjects: 46
Study 35789454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-borne expander
Number of subjects: 46